Outcomes for and risk factors associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant Enterococcus faecium bacteremia in cancer patients

Infection Control and Hospital Epidemiology

Volumn 28, Issue 9, 2007, Pages 1054-1059

  Ghanem, G ^a   Hachem, Ray ^a   Jiang, Y ^a   Chemaly, R F ^a   Raad, I ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CARBAPENEM; CEPHALOSPORIN; GENTAMICIN; METRONIDAZOLE; PENICILLIN G; STREPTOMYCIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; CANCER PATIENT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; OUTCOME ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADULT; AGED; AMINOGLYCOSIDES; BACTEREMIA; CARBAPENEMS; CASE-CONTROL STUDIES; CROSS INFECTION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TEXAS; VANCOMYCIN RESISTANCE;

EID: 34548345798     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/519932     Document Type: Article

References (27)

1. Leclercq R, Derlot E, Duval J, et al. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319:157-161.
2. Sahm DF, Kissinger J, Gilmore MS, et al. In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 1989; 33:1588-1591.
3. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-June 2001, issued August 2001. Am J Infect Control 2001; 29: 404-421.
4. Carmeli Y, Eliopoulos G, Mozaffari E, et al. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002; 162: 2223-2238.
5. Hsueh PR, Chen WH, Teng LJ, et al. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents 2005; 26:43-49.
6. Scagnelli M, Pellizer G, de Lalla F, et al. Epidemiological analysis of vancomycin-resistant enterococci in a large tertiary-care hospital in Northern Italy. Eur J Clin Microbiol Infect Dis 2001; 20:609-616.
7. Wong AH, Wenzel RP, Edmond MB. Epidemiology of bacteriuria caused by vancomycin-resistant enterococci: a retrospective study. Am J Infect Control 2000; 28:277-281.
8. Schouten MA, Voss A, Hoogkamp-Korstanje JA; The European VRE Study Group. Antimicrobial susceptibility patterns of enterococci causing infections in Europe. Antimicrob Agents Chemother 1999; 43:2542-2546.
9. Edmond MB, Ober JF, Dawson JD, et al. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996; 23:1234-1239.
10. Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996; 22: 663-670.
11. American College of Chest Physicians / Society of Critical Care Medicine Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874.
12. Shankar N, Baghdayan AS, Gilmore MS. Modulation of virulence within a pathogenicity island in vancomycin-resistant Enterococcus faecalis. Nature 2002; 417:746-750.
13. Tendolkar PM, Baghdayan AS, Shankar N. Pathogenic enterococci: new developments in the 21st century. Cell Mol Life Sci 2003; 60:2622-2636.
14. Liornese LL, Dias S, Samel C, Romanowski B, et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 1992; 117:112-116.
15. Zirakzadeh A, Patel R. Vancomycin-resistant enterococci: colonization, infection, detection, and treatment. Mayo Clin Proc 2006; 81:529-536.
16. Hayden MK, Bonten MJ, Blom DW, et al. Reduction in acquisition of vancomycin-resistant Enterococcus after enforcement of routine environmental cleaning measures. Clin Infect Dis 2006; 42:1552-1560.
17. Martinez JA, Ruthazer R, Hansjosten K, et al. Role of environmental contamination as a risk factor for acquisition of vancomycin-resistant enterococci in patients treated in a medical intensive care unit. Arch Intern Med 2003; 163:1905-1912.
18. Chavers LS, Moser SA, Funkhouser E et al. Association between antecedent intravenous antimicrobial exposure and isolation of vancomycin-resistant enterococci. Microb Drug Resist 2003; 9(suppl 1):S69-S77.
19. Suntharam N, Lankford MG, Trick WE, et al. Risk factors for acquisition of vancomycin-resistant enterococci among hematology-oncology patients. Diagn Microbiol Infect Dis 2002; 43:183-188.
20. Carmeli Y, Samore MH, Huskins C. The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: a meta-analysis. Arch Intern Med 1999; 159:2461-2468.
21. Furtado GH, Mendes RE, Pignatari AC, et al. Risk factors for vancomycin-resistant Enterococcus faecalis bacteremia in hospitalized patients: an analysis of two case-control studies. Am J Infect Control 2006; 34: 447-451.
22. Noskin GA, Peterson LR, Warren JR. Enterococcus faecium and enterococcus faecalis bacteremia: acquisition and outcome. Clin Infect Dis 1995; 20:296-301.
23. Jones RN, Sader HS, Erwin ME, et al.; Enterococcus Study Group. Emerging multiply-resistant enterococci among clinical isolates: prevalence data from 97-medical center surveillance study in the United States. Diagn Microbiol Infect Dis 1995; 21:85-93.
24. Eliopoulos GM, Wennersten C, Zighelboim-Daum S, et al. High-level resistance to gentamicin in clinical isolates of Streptococcus (Enterococcus) faecium. Antimicrob Agents Chemother 1988; 32:1528-1532.
25. Jett BD, Huycke MM, Gilmore MS. Virulence of enterococci. Clin Microbiol Rev 1994; 7:462-478.
26. Vanholder R, De Smet R, Jacobs V, et al. Uraemic toxic retention solutes depress polymorphonuclear response to phagocytosis. Nephrol Dial Transplant 1994; 9:1271-1278.
27. Willems RJL, Top J, Van Santen M, et al. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 2005; 11:821-828.